![]() Intracranial hemorrhage is a serious, life-threatening condition associated with anticoagulation therapy. Our analysis revealed that the quantitative in-hospital mortality in idarucizumab/dabigatran-treated patients with ICH is estimated to be 9.7–11.4%. Idarucizumab is indicated in dabigatran-treated patients with life-threatening conditions, such as uncontrolled bleeding, or the need for urgent intervention. Idarucizumab is a specific reversal agent of dabigatran, which achieves instantaneous reversal of anticoagulation after application. In-hospital mortality rate was 11.4% in the case series and 9.7% in the case reports.Ĭonclusions: Our analysis provides clinically relevant quantitative data regarding in-hospital mortality in idarucizumab/dabigatran-treated patients with ICH, which is estimated to be 9.7–11.4%. Results: We identified six eligible studies (case series) with 386 patients and 54 single case reports. The assessed outcome was in-hospital mortality. Method: We searched PubMed and Scopus for all published cases of ICH in idarucizumab/dabigatran-treated patients until May 15, 2021. We aimed to estimate in-hospital mortality rate in these patients. Objectives: A review of all published dabigatran-related ICH cases treated with idarucizumab was performed. Systematic review of real-life mortality in these patients is missing. Idarucizumab is used in dabigatran-treated patients suffering from intracranial hemorrhage (ICH) to reverse the anticoagulant effect of dabigatran. ![]()
0 Comments
Leave a Reply. |